Adjuvant Therapy News and Research RSS Feed - Adjuvant Therapy News and Research

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.
Penn Medicine announces recipients of new Basser External Research Grant Program

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration. [More]
Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. [More]
Current smokers at increased risk of developing SPLC

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. [More]
Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]
Integrated therapies can reduce depression by half among people with low vision due to AMD

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD). [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
MD Anderson study shows that needle biopsy underused in breast cancer patients

MD Anderson study shows that needle biopsy underused in breast cancer patients

Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center. [More]
Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study. [More]
ASTRO’s guideline details use of adjuvant radiation therapy in treatment of endometrial cancer

ASTRO’s guideline details use of adjuvant radiation therapy in treatment of endometrial cancer

The American Society for Radiation Oncology (ASTRO) has issued a new guideline, "The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. [More]
Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Rural residents who commonly seek treatment for advanced stages of colorectal cancer have been thought to lack access to cancer screening and adjuvant therapy. ... Several theories have been postulated to explain these findings, some of which include low socioeconomic status, lower educational attainment, lack of insurance coverage, underinsurance, and travel distance to health care facilities. [More]
RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck. [More]
Discovery could lead to new therapies for people with celiac disease

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder. [More]
Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic analyses of results from 1125 postmenopausal women being treated for oestrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five. [More]
Lymphatic invasion indicates prognosis for lung cancer patients

Lymphatic invasion indicates prognosis for lung cancer patients

The presence of lymphatic invasion indicates a worse prognosis for patients with pathologically node-positive lung adenocarcinoma, compared with its absence, indicate Japanese study findings. [More]
Positive margins have limited impact on RCC outcome

Positive margins have limited impact on RCC outcome

Positive vascular wall margins are not associated with systemic recurrence or cancer-specific survival in patients with nonmetastatic renal cell carcinoma with tumour thrombus, US research shows. [More]
Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved. [More]
RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. [More]
New drug combination therapy effective for patients with HER2-positive breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. [More]